Penumbra, Inc.
Financials
Valuation Metrics
Penumbra, Inc.'s Market Cap is $12.71B. At end of 2025 it was $12.18B. Ranked #815 of 3,112 in US market (top 26%), #567 of 1,667 on NYSE (top 34%), #52 of 206 in Health Care Equipment & Services (top 25%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $12.71B | US#815/3,112 Sec#52/206 |
| Revenue | $1.50B | US#1,656/3,112 Sec#100/206 |
| Net Income | $161M | US#1,372/3,112 Sec#66/206 |
| Total Assets | $1.97B | US#2,078/3,112 Sec#106/206 |
| Net Assets | $1.53B | US#1,457/3,112 Sec#76/206 |
| Employees | 4,700 | US#865/3,112 Sec#73/206 |
| Value | ||
| P/E | 79.13x | US#2,010/3,112 Sec#102/206 |
| P/B | 8.30x | US#2,516/3,112 Sec#165/206 |
| P/S | 8.44x | US#2,589/3,112 Sec#181/206 |
| EV/EBITDA | 60.30x | US#2,383/3,112 Sec#127/206 |
| FCF Yield | 1.70% | US#2,015/3,112 Sec#130/206 |
| Profitability | ||
| ROE | 10.49% | US#1,312/3,112 Sec#63/206 |
| ROA | 8.13% | US#602/3,112 Sec#36/206 |
| Op. Margin | 12.45% | US#1,425/3,112 Sec#61/206 |
| Revenue Growth | 14.90% | US#972/3,112 Sec#64/206 |
| Earnings Growth | -23.10% | US#1,693/3,112 Sec#87/206 |
| Financial Health | ||
| Debt Ratio | 29.00% | US#323/3,112 Sec#37/206 |
| Total Debt | $213M | US#2,162/3,112 Sec#116/206 |
| FCF | $216M | US#1,315/3,112 Sec#77/206 |
| Cash | $205M | US#1,706/3,112 Sec#100/206 |
| Current Ratio | 5.75x | US#419/3,112 Sec#32/206 |
| Net Debt/EBITDA | 0.04x | US#653/3,112 Sec#41/206 |
| Performance | ||
| 1Y Return | 32.95% | US#1,073/3,112 Sec#68/206 |
| 1M Return | 1.41% | US#1,445/3,112 Sec#98/206 |
| From 52W High | -10.86% | US#1,109/3,112 Sec#81/206 |
| 1Y MDD | -24.20% | US#983/3,112 Sec#22/206 |
| Trading | ||
| Volume | 247,910 shares | US#2,533/3,112 Sec#181/206 |
| Trading Value | $80M | US#1,048/3,112 Sec#85/206 |
| Per Share | ||
| EPS | $4.53 | US#708/3,112 Sec#45/206 |
| BPS | $36.43 | US#678/3,112 Sec#46/206 |
Company Info
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.